sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysls patients

Journal of Endocrinological Investigation

Volumn 30, Issue 9, 2007, Pages 762-766

  Doumouchtsis, K K ^a,d   Kostakis, A I ^b   Doumouchtsis, S K ^a   Tziamalis, M P ^c   Tsigris, C ^b   Kostaki, M A ^a   Perrea, D N ^a  

^a Laboratory of Experimental Surgery   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c General Hospital of Kastoria   (Greece)

^d NONE   (Greece)

Author keywords

Biochemical markers; Hemodialysis; Male female patients; Osteoprotegerin; SRANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM SALT; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SEVELAMER; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE REMODELING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIALYSATE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 36949015597     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350814     Document Type: Article

References (22)

1. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93: 165-76.
2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95: 3597-602.
3. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998, 246: 199-204.
4. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998, 188: 997-1001.
5. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145: 527-38.
6. Quinn JM, Gillespie MT. Modulation of osteoclast formation. Biochem Biophys Res Commun 2005, 328: 739-45.
7. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309-19.
8. Hakeda Y, Kobayashi Y, Yamaguchi K, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 1998, 251: 796-801.
9. Akatsu T, Murakami T, Nishikawa M, et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by inteffering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998, 250: 229-34.
10. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142: 5050-5.
11. Gonzalez EA. The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000, 15: 945-50.
12. Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002, 17: 233-8.
13. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39: 525-32.
14. Kazama JJ, Kato H, Sato T, et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002, 17: 1860-1.
15. Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NFkappaB ligand derived from osteoblasts. J Immunol 2007, 178: 192-200.
16. Khosla S, Arrighi HM, Melton LJ, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002, 13: 394-9.
17. Liu JM, Zhao HY, Ning G, et al. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. Zhonghua Nei Ke Za Zhi 2004, 43: 447-50.
18. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999, 14: 518-27.
19. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 2006, 1068: 173-9.
20. Doi S, Yorioka N, Masaki T, Ito T, Shigemoto K, Harada S. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial 2004, 8: 335-9.
21. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001, 86: 3162-5.
22. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003, 115: 291-7.